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Abstract
Background: There is increasing interest in hormone replacement therapy to improve health and quality of life (QoL)
of older men with age-related decline in hormone levels. This paper reports the preliminary development and evaluation
of the psychometric properties of a new individualised questionnaire, the A-RHDQoL, measuring perceived impact of
age-related hormonal decline on QoL of older men. A-RHDQoL design was based on the HDQoL for people with
growth hormone (GH) deficiency and the ADDQoL (for diabetes).
Methods: Internal consistency reliability and some aspects of validity of the A-RHDQoL were investigated in a cross-
sectional survey of 128 older men (age range: 64 – 80 yrs), being screened for inclusion in a trial of GH and testosterone
(T) replacement, and who completed the A-RHDQoL once. Respondents rated personally applicable life domains for
importance and impact of their hormonal decline. A single overview item measured present QoL. Serum levels of Insulin-
like Growth Factor-I and total T were measured.
Results: Of the 24 A-RHDQoL domains, 21 were rated as relevant and important for older men. All domains were
perceived as negatively impacted by hormonal decline. The most negatively impacted domains were: memory (-4.54 ±
3.02), energy (-4.44 ± 2.49), sex life (-4.34 ± 3.08) and physical stamina (-4.29 ± 2.41), (maximum range -9 to +9). The
shorter 21-domain A-RHDQoL had high internal consistency reliability (Cronbach's alpha coefficient = 0.935, N = 103)
and applicable domains could be weighted and summed into an overall Average Weighted Impact score. The
questionnaire was acceptable to the majority of respondents and content validity was good. The single overview item
measuring present QoL correlated significantly with total T levels [r = 0.26, p <0.01, N = 114].
Conclusion: The new 21-item A-RHDQoL is an individualised questionnaire measuring perceived impact of age-related
hormonal decline on the QoL of older men. The internal consistency reliability and content validity of the A-RHDQoL
are established, but the measure is at an early stage of its development and its sensitivity to change and other
psychometric properties need now to be evaluated in clinical trials of hormone replacement in older men.
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People aged over 60 now constitute about 20% of the
population in more developed regions of the world; by
2050 they will probably account for 33% [1]. However, a
proportion of the additional years gained with increasing
life expectancy are associated with increasing poor health
and disability. Common changes affecting older men
include a general decrease in well-being, work capacity,
reduced muscle mass and strength, reduced virility, libido
and sexual activity, increased central adiposity, atheroscle-
rosis, impaired cognitive performance and sleep distur-
bances. Many of these changes resemble phenomena
found in well-recognised hormone deficiencies such as
hypogonadism and adult growth hormone deficiency
(GHD) [2]. Growth hormone (GH) secretion declines in
adulthood with a parallel fall in Insulin-like Growth Fac-
tor-I (IGF-I), such that 30% of older men (over 60 years)
have been found to be GH deficient compared to healthy
young adults [3]. Levels of testosterone (T) also fall as
men get older (1–2% per year after 30 years of age) [4]. In
patients with organic GHD, GH replacement improves
body composition, muscle strength, bone mass and sense
of well-being [5] as well as cardiovascular risk factors [6].
Androgen replacement improves body composition [7]
and sexual function [8]. Hormone replacement therapy
has been available to post-menopausal women for some
time. The question has now arisen whether older men
might also benefit from hormone replacement to help
reduce and prevent frailty [9] and prolong the capacity for
independent living [10].
In older people GH treatment improves muscle mass and
strength [11] and bone mineral density [12]. T treatment
given to healthy older men increases bone mineral density
[13], increases lean body mass and decreases body fat
[14]. Combined GH and sex steroid administration
improves body composition, muscle strength (margin-
ally) and maximum oxygen uptake during exercise
[15,16]. Higher bioavailable T levels have been associated
with improved cognitive function [17], and reduced
depression [18]. However, side effects such as carpal tun-
nel syndrome, arthralgia and hyperglycaemia are com-
mon with GH therapy, and T administration may also
have side effects, e.g. gynaecomastia and skin irritation
with T patches [19].
These and many other studies indicate the increasing
interest in determining whether normalisation of hor-
mone levels in older men leads to improvements in both
physical and psychological functioning. Few studies, how-
ever, have measured quality of life (QoL), or the patient
reported outcomes of health status and psychological
well-being. The Short-Form Health Survey, (SF-36), [20],
a health status measure, found a significant increase in
physical functioning following T supplementation in one
study [21] but no significant effects in other studies
[22,23]. The Psychological General Well-being Index
(PGWB) [24], a measure of psychological well-being, did
not find any significant effects after 8 weeks T supplemen-
tation [23]. As pointed out elsewhere [25], such generic
measures of health status and well-being may not be suf-
ficiently sensitive, nor are they measures of QoL, although
often described as such. However, QoL is an important
outcome of clinical trials and with increasing research on
hormone replacement in older men there is an urgent
need for a measure of QoL for use in this field.
The Age-Related Hormone Deficiency-Dependent Quality
of Life Questionnaire (A-RHDQoL) is a new individual-
ised questionnaire designed to measure the QoL of older
men with age-related hormonal decline. This paper con-
cerns the evaluation of the psychometric properties of this
questionnaire in a sample of older men who had volun-
teered for a trial of GH and T replacement therapy at St
Thomas' Hospital, London and were being screened for
their suitability for inclusion in the trial. The Guy's and St
Thomas' Hospital Trust Research Ethics Committee gave
approval for the study (EC 99/154).
Methods
The A-RHDQoL
Design of the A-RHDQoL was influenced by work on the
Schedule for the Evaluation of Individual Quality of Life
(SEIQoL) [26], the Audit of Diabetes-Dependent Quality
of Life (ADDQoL) [27,28] and subsequent adaptations of
the ADDQoL for people with macular degeneration
(MacDQoL) [29], and with adult GHD, (the HDQoL)
[30,31]. The HDQoL was found to have high internal con-
sistency reliability, and to be sensitive to change and to
sub-group differences in adult GHD [30,32,33]. Although
patients were involved in generating versions of this
instrument for these disorders (through interviews and
solicited written comments), time constraints prevented
qualitative research with older men with age-related hor-
monal decline. Superficial adjustments were therefore
made to the HDQoL to make it suitable for these older
men. Nineteen of the 24 A-RHDQoL life domains are in
the latest version of the HDQoL, and include domains of
family, social, working and sex life, physical aspects such as
physical capabilities, appearance, stamina, sleep and pain, and
psychological aspects such as confidence and motivation.
Additional domains of health, fertility, concentration, house-
hold tasks, and society's reaction were derived from the
MacDQoL, and from a review of the literature as well as
discussions with health professionals. (The Results sec-
tion provides details of the final selection of items follow-
ing psychometric analyses). At the end of the
questionnaire there is a 'free comments' section in which
respondents are asked if there are any other ways in which
they perceive age-related decline in hormone levels toPage 2 of 12
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of further domains to the questionnaire in the future as
part of its continuing development.
The first two items in the questionnaire provide an over-
view of the respondent's QoL. Question I asks respond-
ents to rate their present QoL on a 7-point scale from 'as
good as it could possibly be' to 'as bad as it could possibly
be'. Question II asks them to rate what their QoL would
be if they did not have age-related decline in hormone lev-
els, on a 7-point scale from 'very much better' to 'very
much worse', providing a global measure of impact of age-
related hormonal decline on QoL. Like the ADDQoL and
its related questionnaires, the A-RHDQoL is individual-
ised. It takes into account the relevance for the individual
of each aspect of life or domain covered in the question-
naire, by giving men the opportunity to indicate whether
a particular domain is not applicable (N/A), specifically in
questions concerning work, family, sex life, fertility, and
pain. The impact of age-related decline in hormone levels
on each relevant domain is then assessed as well as its per-
ceived importance to the individual. Each domain is
introduced by the hypothetical statement: If my hormone
levels had not declined with age, my [domain] would be......
and is followed by a 7-point Likert scale from 'very much
better' to 'very much worse' (the impact rating). Respond-
ents then rate how important that domain is to them on a
4-point Likert scale from 'very important' to 'not at all
important'. Owing to time restrictions only a small pilot
study could be conducted (N = 3) but this found the ques-
tionnaire acceptable to respondents and no additional
domains were suggested.
Scoring
The domain impact ratings are scored from -3 to +3 as
shown in Fig. 1. Importance ratings are scored from 0 (not
at all important) to 3 (very important). A weighted domain
impact score is obtained by multiplying the domain's
impact rating by the corresponding importance rating. For
example, if a respondent indicated that a domain would
be much better (score -2) if he did not have age-related
hormonal decline, and that the domain was very impor-
tant to him (score 3), the weighted domain score would
be -6. An overall score for the questionnaire, the A-
RHDQoL Average Weighted Impact score (A-RHDQoL
AWI) is obtained by summing all applicable weighted
domain scores, before dividing by the number of domains
applicable to the individual. Weighted domain scores and
A-RHDQoL AWI range from -9 to +9 (maximum negative
to maximum positive impact of age-related hormonal
decline on the individual domain or on overall QoL). The
number of applicable domains excludes all domains
marked N/A. The overview items are not weighted by
importance ratings, but Question II – impact on QoL (QII)
is scored in the same way as the domains, from -3 to + 3.
Question I – present QoL (QI), however, is scored +3 to -3
from 'as good as it could possibly be' to 'as bad as it could pos-
sibly be', so that a higher score indicates better QoL.
Example of an A-RHDQoL domain item and scoringFigure 1
Example of an A-RHDQoL domain item and scoring
9a) If my hormone levels had not declined with age, my sex life would be:
very much 
better
much 
better
a little 
better
the same a little 
worse
much 
worse
very much 
worse
9b) This aspect of my life is:
not 
applicable
very
important
important somewhat 
important
not at all 
important
-2 -1 0 1 2 3
03 2 1
-3Page 3 of 12
(page number not for citation purposes)
Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/51Other questionnaires used in the study
Two well-established generic questionnaires were also
completed in the screening study: the SF-36 [20], and the
12-item Well-being Questionnaire (W-BQ12) [34,35].
They were selected to provide additional data on health
status and well-being and, although their data were used
to investigate correlations with A-RHDQoL variables,
high correlations were not expected as neither measures
QoL. The SF-36 has 8 subscales to measure Bodily Pain,
General Health, Mental Health, Physical Functioning,
Role-Emotional, Role-Physical, Social Functioning and
Vitality. Scores on the SF-36 range from 0 to 100 (poor to
good health status). The W-BQ12 has 3 subscales to meas-
ure Negative Well-being, Energy and Positive Well-being
and a combined General Well-being scale. Subscale scores
range from 0 to 12 (higher scores indicating increased
mood of the subscale label) and the total score ranges
from 0 to 36 (a higher score indicates better well-being).
Recruitment
The participants were older men who had volunteered for
a 6-month randomised controlled trial of GH and T
replacement (HRT trial) at St Thomas' Hospital, London,
in response to advertisements and articles in the national
and local press, and were undergoing screening for inclu-
sion in this trial. The advertisements stated that the trial
was to investigate whether GH and T treatment would
improve general well-being, strength, exercise tolerance
and cholesterol levels in older men. Volunteers completed
a pre-screening questionnaire to indicate whether they fit-
ted the inclusion and exclusion criteria for participation in
the clinical trial. The inclusion criteria were male sex, and
age 65–80 years. Exclusion criteria were clinically signifi-
cant pulmonary, cardiac, hepatic, renal, psychiatric or
progressive neurological disease, uncontrolled hyperten-
sion and/ or diabetes, any evidence of active malignancy
or a history of prostate cancer, any history of pituitary dis-
ease, obesity (body mass index > 30 kg/m2), taking
corticosteroids, appetite suppressants drugs or other drugs
that affect bone metabolism.
Factor analyses ideally require a minimum of 5 respond-
ents per questionnaire item [36] thus analyses of the 24-
item A-RHDQoL required a minimum of 120 completed
questionnaires. However, screening for the HRT trial had
already started before the full 24-item questionnaire was
ready for use, and only 64 completed A-RHDQoL ques-
tionnaires were obtained at screening. Volunteers who
had not completed this questionnaire at screening were
later approached by mailshot (i.e. by post). The question-
naire was enclosed with a letter in which the volunteers
were informed that they would not be invited to partici-
pate in the HRT trial because their hormonal levels were
insufficiently low. (These volunteers would have exhib-
ited similar age-related hormonal decline to some of the
64 volunteers in the initial screening, who completed the
questionnaire, but who were also not invited to partici-
pate in the trial, as a result of insufficient hormonal
decline). Finally, the baseline data were used from HRT
trial participants who had not completed the A-RHDQoL
at the screening stage. There were thus 3 methods of
recruitment:
(1) Volunteers at initial screening (N = 64)
(2) Post-screening mailshot of volunteers (N = 12)
(3) HRT trial participants, baseline data (N = 53);
Total number of recruits = 129.
Statistical analyses
The 'Not Applicable' response option and loss of data
None of the data from any respondent who selected a N/
A response option would normally be included in factor
and reliability analyses, because N/A responses are treated
as missing by the statistical package used in these analyses
(SPSS for Windows, Release 9.0). Furthermore, if the SPSS
default of listwise deletion of missings is used, all cases
that have any missing values across all 24 items are lost to
analysis, so considerable data could be lost. As will be
seen below, between 3 to 40% of volunteers chose a N/A
option. N/A responses were therefore set to zero for one
set of analyses, with pairwise deletion of missings as in the
original development of the ADDQoL [27]. (Pairwise
deletion minimises loss of data because only cases with
missing values for one or both of a pair of variables in a
correlation are excluded from the analysis, however, this
can result in a set of coefficients based on a varying
number of cases). Results obtained from a second set of
analyses, when N/A responses were coded as missing with
listwise deletion of missings, are also reported where
relevant.
Normality issues
Normality of distributions was determined through inves-
tigation of histograms and z (skew) scores, where z (skew)
scores ≥ ± 2.58 are indicative of non-normality [37]. The
A-RHDQoL is not a questionnaire where a normal spread
of scores and normal distributions would be expected.
The bi-polar scale allows for some respondents to have
positive scores, indicating their perception that hormonal
decline had some positive effects on their lives, but these
were expected to be uncommon. Item data were trans-
formed as near to normality as possible. The assumption
was made that if the reliability of the scale was high, and
the number of respondents sufficiently great, then a
robust factor analysis should override the problem of
non-normality.Page 4 of 12
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Cronbach's alpha coefficient of internal consistency relia-
bility was determined. An alpha of 0.8 was taken as the
minimum acceptable [38], but 0.9 was preferable as it is
considered by some to be the minimum for measures of
differences between individuals [39]. Acceptable item-
total correlations were those >0.2 [40].
Factor structure
This was explored by Principal Components Analysis with
Varimax rotation, (a rotation that minimises the correla-
tion between components). Salient loadings were taken as
≥ 0.4. This is higher than the recommended minimum 0.3
[41], erring on the side of caution in an effort to reduce
the risk of spurious loadings that owed their origin to
non-normality of item distributions, and also to avoid
double loadings.
Correlations
Correlations were run on relationships between A-
RHDQoL variables and Body Mass Index (BMI), age, lev-
els of total T and IGF-I (the marker for GH levels), as well
as SF-36 and W-BQ12 subscales. It was not appropriate to
consider the correlations with SF-36 and W-BQ12 ques-
tionnaires as measures of concurrent validity as the A-
RHDQoL measures different experiences (QoL and per-
ceived impact of age-related hormonal decline on QoL)
from these measures of health status and well-being.
Small to moderate correlations only were anticipated,
though significance was likely with this sample size. Cor-
relations were investigated using Pearson's r for paramet-
ric, and Spearman's rho for non-parametric variables.
'Familywise' error in multiple tests
The Bonferroni correction for familywise error was
adopted (i.e. alpha was set initially to 0.05/n where n was
the number of variables within a 'family' and then the
Holm's sequential Bonferroni procedure for multiple tests
was applied [42] whereby the family size reduces with
each significant result. For example if 3 similar statistical
tests were performed on A-RHDQoL AWI score and the A-
RHDQoL overview items, QI and QII, (regarded as one
'family'), the minimum significance value of each sequen-
tial significant result would be 0.017, 0.025, and 0.05.
Correlations of A-RHDQoL AWI and the 2 overview items
with the 3 subscales and total score of the W-BQ12 (12
pairs of correlations) would require sequential signifi-
cance values of 0.0042, 0.0045, 0.005 etc. Correlations
with the 8 subscales of the SF-36 (24 pairs of correlations)
would require sequential significance values of 0.0021,
0.0022, 0.0023 etc.
Results
A-RHDQoL completion rates
One of the 129 returned questionnaires had no items
completed and this was not included in analyses. Com-
pletion rates of the 128 completed A-RHDQoL question-
naires were as follows: impact ratings (98.1%),
importance ratings (97.2%), indicating good acceptability
to respondents.
The study sample characteristics
The average age of the sample was 70.2 years, and the
mean age of leaving full-time education was 17.3 years.
(See Table 1 for sample characteristics). Three volunteers
reported stable disabilities (caused by blindness in one
eye, osteoarthritis, loss of finger respectively). Forty-two
(32.8%) reported no illnesses. Frequencies of reported ill-
nesses were: osteoarthritis or other bone problem (19),
hypertension (18), cardiovascular disease (10), benign
prostate disease (9), bronchial disorder (9), digestive sys-
tem disorder (6), skin disorder (3), and non-prostate can-
cer (3). None of these were considered severe enough to
preclude invitation to screening for inclusion in the clini-
cal trial.
Initial analyses to show that the 3 recruitment samples 
could be treated as one
Preliminary analyses were undertaken to check that there
were no significant differences caused by the 3 recruit-
ment procedures, using methods adopted in the develop-
ment of the ADDQoL [27]. Item scores on the A-RHDQoL
(brought as close as possible to normality) were first con-
verted to z scores for each of the 3 subgroups and then
recombined. All items on the questionnaire were forced
onto one factor in Principal Components Analyses of
recombined z scores and raw weighted scores. Loadings
thus obtained were then compared by regression analysis.
Regression analysis showed no significant difference
between the loadings of standardized and raw scores. The
correlation of 0.993 was close to a perfect 1, the constant
(0.053) did not differ significantly from zero (t = 3.72, df
= 23, p < 0.01) and the slope of the regression line (0.914)
did not differ significantly from 1, (t = 39.8, df = 23, p <
0.0001). Thus the initial analyses demonstrated that the 3
recruitment subgroups could be treated as one for the pur-
poses of reliability and factor analyses, (for which a larger
N is desirable).
Table 1: Demographic and other sample characteristics
Mean ± S.D.
Age (years) 70.17 ± 3.69
Age at leaving full-time education 17.25 ± 3.24
Body Mass Index (kg/m2) 26.24 ± 3.07
Total T levels (nmol/l)* 15.59 ± 5.58
IGF-I levels (nmol/l)** 15.26 ± 4.95
*Total T reference range for young males: 10 – 30 nmol/l **IGF-I 
reference range for young males: 12.8 – 62.2 nmol/lPage 5 of 12
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On the basis of early frequency, reliability and forced 1-
factor analyses, 3 domain items (fertility, finances and
depend) were deleted from the scale for the following
reasons:
• Severe non-normality of distributions (fertility; finances;
depend).
• A high proportion of volunteers regarded the domain as
either not applicable [fertility (39.8%)] or not important
[fertility (56.3%)].
• A high proportion of volunteers perceived age-related
hormonal decline as having no impact on the domain
[fertility (74.0%); finances (79.4%); depend (59.5%)].
• Items did not contribute to overall scale reliability in a
reliability analysis where Cronbach's alpha was 0.933 (N
= 100, N/A responses coded as zero): ['alpha if item
deleted' for fertility and depend was 0.936 and 0.934
respectively].
• Unsatisfactory item-total correlation: [fertility (0.126)].
• A low and unsatisfactory loading on a forced 1-factor
analysis [fertility (0.051); depend (0.288)].
Analysis of the 21-item A-RHDQoL
Descriptive statistics
Domains perceived to be most severely (and negatively)
impacted by age-related hormonal decline were: memory
(-4.54 ± 3.02), energy (-4.44 ± 2.49), sex life (-4.34 ± 3.08)
and physical stamina (-4.29 ± 2.41), (maximum range -9 to
+9). The least impacted domains were: society's reaction (-
1.31 ± 1.91), worry about future (-1.45 ± 2.21), and bodily
pain (-1.46 ± 2.05). (See Fig. 2). The A-RHDQoL AWI
score was -2.79 ± 1.63, indicating an overall negative per-
ceived impact of hormonal decline on QoL, although the
mean for overview item QII – impact on QoL was less neg-
ative (-1.5 ± 1.05, score range -3 to 2). The men perceived
their current QoL to be between good and very good
(mean QI – present QoL was 1.51 ± 0.84, score range -2 to
+3). Percentages of volunteers choosing the N/A response
option were: work (34%), bodily pain (19%), family (8%)
and sex life (3%).
Mean weighted impact scores of A-RHDQoL domains and Average Weighted Impact score (N = 128)Figure 2
Mean weighted impact scores of A-RHDQoL domains and Average Weighted Impact score (N = 128)
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dealt with by reducing outlier scores and then conducting
reflect and log transformations, leaving 5 items with a
small degree of non-normality [z (skew) ranging from 3.0
to 5.9].
Reliability analyses
Reliability analyses showed the 21-item A-RHDQoL to
have high internal consistency reliability: Cronbach's
alpha was 0.935, N = 103 (N/A coded as zero), or 0.923,
N = 55 (N/A coded as missing). All item-total correlations
were satisfactory (>0.2), the lowest being work (0.358).
The only items to detract slightly from the overall scale
alpha were sleep and work (overall alpha with either item
deleted was 0.936, N/A coded as zero). (See Table 2).
Note: If reliability and factor analyses were run with N/A
coded as missing only 55 cases were available for analysis
because any volunteer responding N/A in any of the 4
items with N/A response options would be lost to analy-
sis. This increased to 103 when N/A was coded as zero,
still short of the full number of participants owing to
missing data in other variables without N/A response
options.
Dealing with missing data
To assess the effects of missing data on the measure's reli-
ability, reliability analyses were run sequentially deleting
Table 2: Reliability of the 21-item A-RHDQoL (N/A responses coded as zero)
A-RHDQoL domain Scale mean if item 
deleted
Scale variance if item 
deleted
Corrected item-total 
correlation
Alpha if item deleted
1. Family life* 21.86 1.13 0.68 .9310
2. Social life 21.89 1.15 0.62 .9322
3. Work* 21.92 1.21 0.36 .9359
4. Health 21.85 1.13 0.72 .9304
5. Physical appearance 21.86 1.17 0.55 .9332
6. Physical capabilities 21.81 1.13 0.74 .9301
7. Physical stamina 21.81 1.15 0.63 .9320
8. Energy 21.80 1.14 0.70 .9309
9. Sex life* 21.82 1.14 0.53 .9342
10. Sleep 21.88 1.16 0.43 .9364
11. Bodily pain* 21.91 1.19 0.45 .9348
12. Stress-tolerance 21.88 1.13 0.64 .9318
13. Memory 21.81 1.11 0.69 .9308
14. Concentration 21.83 1.11 0.76 .9295
15. Travel 21.89 1.15 0.69 .9312
16. Holidays & leisure 21.87 1.13 0.67 .9312
17. Household tasks 21.88 1.14 0.64 .9317
18. Confidence 21.87 1.13 0.72 .9303
19. Motivation 21.87 1.13 0.70 .9306
20. Society's reaction 21.90 1.18 0.50 .9341
21. Worry about future 21.90 1.16 0.56 .9332
Cronbach's alpha for 21-item A-RHDQoL = 0.935, (N = 103). Standardized item alpha = 0.936.
Table 3: Forced 1-factor loadings of the 21-item A-RHDQoL (N/
A responses coded as zero)
1. Family life* 0.725
2. Social life 0.689
3. Work* 0.378
4. Health 0.749
5. Physical appearance 0.592
6. Physical capabilities 0.770
7. Physical stamina 0.684
8. Energy 0.742
9. Sex life* 0.555
10. Sleep 0.491
11. Bodily pain* 0.470
12. Stress-tolerance 0.644
13. Memory 0.671
14. Concentration 0.730
15. Travel 0.682
16. Holidays & leisure 0.709
17. Household tasks 0.650
18. Confidence 0.727
19. Motivation 0.715
20. Society's reaction 0.543
21. Worry about future 0.579
Loadings in bold are satisfactory (≥ 0.4). *item has N/A response 
option.Page 7 of 12
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the lowest 'alpha if item deleted' and therefore contribut-
ing most to the internal consistency reliability of the scale)
[43]. Calculation of overall A-RHDQoL AWI score was
reliable at alpha = 0.9 with up to 4 items of missing data
and reliable at alpha = 0.8 with up to 10 items of missing
data, whether N/A responses were coded as zero or miss-
ing. Thus even if a completed questionnaire has some
missing data, the overall A-RHDQoL AWI score can still
be calculated, and that respondent's available data not
lost to analysis.
Factor analyses
Unforced factor analysis
An unforced Principal Components Analysis of the 21-
item A-RHDQoL, with Varimax rotation, produced 5
components with eigen values >1 that accounted for
66.7% of the total variance if N/A responses were coded as
zero, (or 71.0% of the variance if N/A responses were
coded as missing). Several items double loaded and there
was no readily interpretable pattern of factor loadings
(details not shown). The scree plot indicated only 1 strong
factor.
Forced 1-factor analysis
Loadings of the 21-item A-RHDQoL, with N/A responses
coded as zero, found that all items had satisfactory load-
ings (>0.4) except work (0.378). (See Table 3). When N/A
responses were coded as missing, all loadings were satis-
factory except worry about future (0.396), but work loaded
at 0.624 (full details not supplied). Regression analysis
found a moderately high correlation of 0.71 between the
2 sets of loadings (N/A responses coded as zero or miss-
ing). This result supported the calculation of the overall A-
RHDQoL AWI score.
Note: If work were excluded from the forced 1-factor anal-
ysis, all items loaded satisfactorily and in excess of 0.46.
Cronbach's alpha increased by 0.001 to 0.936 and the
only item to detract from alpha was sleep (alpha with item
deleted = 0.937)
Correlations
Biomedical variables
The overview item QI – present QoL showed a small signif-
icant correlation with total T levels (r = 0.26, p < 0.01, N
= 114), indicating deteriorating QoL with decreasing T
levels. There were no other significant correlations (fol-
lowing Bonferroni corrections) between QoL scores and
hormone levels. Correlations with total T levels that
approached significance were: overview item QII – impact
on QoL (r = 0.21, p = 0.026), and domain bodily pain (rho
= 0.27, p = 0.009) (indicating a tendency for greater per-
ceived impact of hormonal decline on QoL, and greater
perceived impact on bodily pain with decreasing T levels).
The only correlation with IGF-I levels that approached sig-
nificance was for the domain stress-tolerance (r = 0.22, p =
0.022) (indicating a tendency for greater perceived impact
on tolerance of stress with decreasing IGF-I levels). There
were no significant correlations with BMI or age.
Table 4: Correlations of the A-RHDQoL with SF-36 and W-BQ12 variables
A-RHDQoL
Average Weighted Impact Overview item QI -present QoL Overview item QII -impact on QoL
WBQ-12
Positive Well-being 0.41** 0.47** 0.32**
Energy 0.43** 0.36** 0.37**
Negative Well-being† -0.23* -0.20 -0.13
General Well-being total 0.40** 0.48** 0.34**
SF-36
Bodily Pain 0.23 0.17 0.08
General Health 0.33** 0.36** 0.26**
Mental Health 0.30** 0.41** 0.20
Physical Functioning 0.31** 0.32** 0.17
Role-Emotional 0.25** 0.39** 0.06
Role-Physical 0.29** 0.27** 0.06
Social Functioning 0.33** 0.32** 0.21
Vitality 0.30** 0.46** 0.28**
Significant at **p < 0.01 and *p < 0.05 (2-tailed) after Bonferroni corrections. Correlations of all SF-36 subscales, W-BQ12 Negative Well-being and 
General Well-being total were Spearman's rho (non-parametric data), and those of W-BQ12 Positive Well-being and Energy were Pearson's r 
(parametric data). N: range 112 – 125. †A high score for W-BQ12 subscales indicates more of the subscale mood, (hence the negative correlations 
between Negative Well-being and A-RHDQoL variables).Page 8 of 12
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Moderately strong positive correlations were found
between A-RHDQoL AWI and all 3 W-BQ12 subscales
and W-BQ12 General Well-being total, and with all SF-36
subscales except Bodily Pain. These indicated that per-
ceived overall impact of age-related hormonal decline on
QoL was inversely related to well-being and health status
as expected. Overview item QI – present QoL correlated
with W-BQ12 General Well-being total and all W-BQ12
subscales except Negative Well-being, and with all SF-36
subscales except Bodily Pain. Overview item QII – impact
on QoL correlated with W-BQ12 General Well-being total
but with fewer subscales (WBQ-12 Positive Well-being
and Energy, and SF-36 General Health and Vitality). (See
Table 4). Some correlations were undertaken of A-
RHDQoL domains with subscales measuring similar
quantities: A-RHDQoL domain social life correlated with
SF-36 Social Functioning (rho = 0.24, p < 0.01), domain
pain with SF-36 Bodily Pain (rho = 0.43, p < 0.001),
domain physical capabilities with SF-36 Physical Function-
ing (rho = 0.26, p < 0.01), domain energy with SF-36 Vital-
ity (rho = 0.25, p < 0.01) and with W-BQ12 Energy (r =
0.37, p < 0.001). These indicated less perceived impact of
the domain on QoL with improving health status or well-
being as expected.
Within the A-RHDQoL
There was a moderately strong correlation between A-
RHDQoL AWI and overview item QII – impact on QoL (r =
0.61, p < 0.001), and a weaker, but still significant, corre-
lation between A-RHDQoL and overview item QI – present
QoL (r = 0.28, p < 0.01).
Free comments section
In the free comments section at the end of the A-RHDQoL
questionnaire, respondents are asked to list any other
ways in which age-related hormonal decline affects their
QoL that have not already been included in the question-
naire. Seventy-three men responded, but when comments
were analysed, the men were emphasising or expanding
on their responses to existing questionnaire domains.
Areas that did not have a specific item in the question-
naire, but were mentioned by at least one respondent
were:
• Loss of physical and muscle strength (N = 5)
• Participation in sports (N = 5)
• Getting overheated and sweaty at night (N = 1)
• Loss of hearing and sight (N = 1) and singing voice (N =
1)
• Depression (N = 1)
• Taking longer to recover from illnesses (N = 1)
• Taking longer to do things (N = 1)
• Stiffness (N = 1).
'Loss of physical strength' is adequately covered by
domains of physical capabilities and physical stamina, and
'participation in sports' is covered by domains holidays/lei-
sure and physical capabilities. They do not appear to warrant
new domains in the questionnaire. Only one respondent
mentioned each of the other areas, insufficient to suggest
the need for new domains. This, taken with the evidence
that all 21 domains were perceived as negatively impacted
by age-related hormonal decline (see Fig. 2), supports the
content validity of the A-RHDQoL.
Eighty-six men responded to the section asking for com-
ments on the A-RHDQoL questionnaire. Seven men (8%)
made positive comments, remarking that the question-
naire was satisfactory, that all relevant areas had been cov-
ered or that they had found it interesting. On the other
hand 12 men (14%) responded that they had had diffi-
culty answering the questionnaire as they had little
knowledge of the effects of declining hormone levels on
QoL. Comments included:
"My answers have been based on the conceptions (? misconcep-
tions) I have gained from observing effects of HRT on my wife"
(age 72).
"Answers to foregoing questions are very subjective because my
understanding of the actual effect of a decline in hormone levels
is nil" (age 68).
"I feel that some questions relating to hormone levels are diffi-
cult to answer unless one has specific knowledge of the subject.
However, I have tried to answer to the best of my scant knowl-
edge – plus a little guess work" (age 70).
"Different hormones have different effects (growth, sex, etc.).
The questions, however, only use the generic term "hormone""
(age 67).
"Subjective answers on subjects I know little about" (age 70).
"It would have helped to know how hormones affect the body
and mind" (age 68).
"How do I know how I would feel if things were different?"
(Respondent aged 77 referring to the hypothetical ques-
tions in the A-RHDQoL).Page 9 of 12
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only, these comments were not considered to be a major
cause for concern.
Discussion
The A-RHDQoL is a new measure of the perceived impact
of age-related hormonal decline on QoL of older men,
and which is still under development. The questionnaire
is individualised because respondents rate only those
domains that are relevant to them, and both the impact of
age-related hormonal decline on life domains and the
importance of each domain to the individual are taken
into account in scoring. Being bi-polar it assesses both
positive and negative impact on QoL, although this
resulted, as expected, in skewed data distributions because
few men perceived any positive benefits of hormonal
decline. There were very high completion rates indicating
that the questionnaire had good acceptability to the great
majority of respondents.
Early psychometric analyses indicated that the original
24-item A-RHDQoL, which had been adapted from the
version for adult GHD, the HDQoL, would be improved
by dropping 3 of the original items. Internal consistency
reliability and item-total correlations were high and factor
analyses highly supportive of the shorter 21-item A-
RHDQoL. The work domain was marked N/A by one third
of respondents, it detracted very little from overall scale
reliability (by 0.001) and produced a loading slightly
lower than the preferred 0.4 on a forced 1-factor analysis
(with N/A responses coded as zero), but had an acceptable
loading if N/A responses were coded as missing. It was
decided to retain work in the questionnaire because it was
reported as relevant and important to the majority or
respondents, and internal consistency reliability was
excellent and very little impaired. There was therefore suf-
ficient evidence from factor analyses to conclude that the
21 items could be summed into a single total, the A-
RHDQoL AWI score.
Useful information can be elicited from the single over-
view items on their own. On average, respondents' current
QoL was perceived to be between good and very good (QI
– present QoL). QII, concerning impact of age-related hor-
monal decline on QoL, could provide an approximate
substitute for the full A-RHDQoL for some purposes, (e.g.
when respondent burden is of particular concern), as the
correlation between QII and overall A-RHDQoL AWI was
moderately high (0.61). Furthermore, rich information
can be obtained by analysing the individual domains sep-
arately, and this could prove useful in studies where there
is interest in the perceived impact of age-related hormonal
decline on specific aspects of life. For example, analysing
the individual domains separately in the present study
showed that age-related hormonal decline was reported as
having the most negative impact on the men's memory,
energy, sex life, and physical stamina.
Insufficient data were collected to support the construct
validity of the A-RHDQoL with regard to sub-group differ-
ences. The small but significant positive correlation of
overview item QI – present QoL with total T levels may be
a preliminary indication of construct validity, but there is
insufficient research evidence to date to support a link
between T levels and QoL. The lack of correlations with
age may reflect the narrow (15-year) age range in this
study. Strong correlations of A-RHDQoL AWI with the SF-
36 and W-BQ12 questionnaires were not expected as the
A-RHDQoL measures neither health status nor well-
being. The small to moderate correlations found sug-
gested that the A-RHDQoL is measuring something
related to, but markedly different from the SF-36 or W-
BQ12, and that neither of those instruments provides a
substitute for the A-RHDQoL. As expected, overview item
QI – present QoL had generally higher correlations with
the SF-36 and W-BQ12 subscales than A-RHDQoL AWI or
overview item QII – impact on QoL. The highest correla-
tions of A-RHDQoL AWI and overview items were found
with W-BQ12 subscales and W-BQ12 General Well-being
total, and these were in the expected direction of decreas-
ing self-reported impact of age-related decline in hor-
mone levels with increasing well-being. Lower but still
significant correlations were found with SF-36 subscales
indicating that health status is a smaller component of
QoL than well-being.
The respondents in this study were a self-selecting group
who had answered advertisements placed in the national
press for volunteers in a trial of GH and T replacement. It
is probable that most of these men were aware that levels
of these hormones decline with age, and perceived that
hormone replacement therapy might be of benefit to their
health and QoL. The great majority therefore had no diffi-
culty in answering questions about the impact of declin-
ing hormone levels on various aspects of life. However, a
minority of respondents (14%) reported (in the free com-
ments section) problems in responding to the hypotheti-
cal items because they lacked knowledge of the effects of
declining hormone levels on QoL. It is possible that some
respondents associated the symptoms of declining hor-
monal levels with those of ageing, and similar item
responses would have been obtained if the question stem
"if my hormone levels had not declined with age....." had been
replaced by "if I were younger....". It is also quite likely that
the majority of men would be unaware that hormones
might affect all the domains covered by the questionnaire,
but that the questionnaire provided them with clues to an
explanation of their symptoms of ageing. In other respects
content validity was supported, as no new domainsPage 10 of 12
(page number not for citation purposes)
Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/51emerged from an analysis of the open section that invited
comments.
Although the A-RHDQoL would be inappropriate for
older men in the general population who were not aware
of the hormonal decline that accompanies ageing, there is
good evidence that it may be suitable for older men par-
ticipating in trials of hormone replacement therapy, as
they will be aware of the age-related decline in hormone
levels. The A-RHDQoL is still under development and fur-
ther studies are needed to assess construct validity
(including sub-group differences), and test-retest reliabil-
ity. The measure's sensitivity to change in the HRT trial
that followed the screening process will be reported in due
course. We recommend that the A-RHDQoL be used in
conjunction with an established measure of health status
(such as the SF-36) and another of well-being (such as the
W-BQ12) to ensure that all areas of QoL and associated
patient-reported outcomes of health status and well-being
are covered.
Conclusion
The A-RHDQoL is a new individualised measure of the
perceived impact of age-related hormonal decline on
QoL, where the relevance and importance of life domains
to an individual's QoL are taken into account in the scor-
ing. Although it is still at an early stage of development,
the 21-item questionnaire is performing well: it has good
acceptability to the great majority of respondents, and
excellent internal consistency reliability. No subscales
emerged, but domains can be analysed separately if
required and an overall score, the Average Weighted
Impact score, calculated. Even at this present stage, the 21-
item A-RHDQoL appears to be a useful tool and its
construct validity (including sensitivity to subgroup dif-
ferences), its test-retest reliability and sensitivity to change
need now to be evaluated in clinical trials of hormone
replacement in older men.
A-RHDQoL copyright
For access to and permission to use the A-RHDQoL, con-
tact the copyright holder, Clare Bradley PhD, Professor of
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0EX.
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